Trial reportCanadian respiratory journal2026
Effect and Safety of Bronchoscopy Based on Imaging Evaluation in Patients With Acute Exacerbation of Bronchiectasis.
Trial report in Canadian respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect and Safety of Bronchoscopy Based on Imaging Evaluation in Patients With Acute Exacerbation of Bronchiectasis.Canadian respiratory journal · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of imaging-assisted bronchoscopic interventions in acute bronchiectasis exacerbations and analyze their effects on pulmonary function, inflammation, and quality of life for evidence-based clinical support.
methodsA total of 80 inpatients with acute bronchiectasis exacerbations were randomized into a control group (n = 40), receiving conventional anti-infective and symptomatic treatment, and an intervention group (n = 40), receiving additional imaging-assisted bronchoscopic intervention. Pulmonary function, inflammatory markers (C-reactive protein [CRP], procalcitonin [PCT], and white blood cell count [WBC]), and St George's Respiratory Questionnaire (SGRQ) quality of life scores were assessed preintervention and at 1, 2, and 4 weeks. Adverse events (e.g., hemoptysis, pneumothorax, and infection spread) and overall effectiveness were recorded.
resultsNo significant intergroup differences were observed in baseline characteristics, preintervention pulmonary function (forced expiratory volume in the first second [FEV
conclusionBronchoscopy intervention guided by imaging improves lung function, reduces inflammation and adverse events, enhances quality of life, and demonstrates good safety with high clinical value in acute bronchiectasis exacerbations. The therapeutic benefit is likely attributable to the bronchoscopic procedure itself, including targeted pathogen identification and subsequent antibiotic modification, rather than solely to transient sputum clearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.